Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SH) announced that its subsidiary, Xuancheng Menovo Pharmaceutical Co., Ltd., recently received the "Chemical Drug Master File Approval Notice" for Atorvastatin Calcium API from the National Medical Products Administration. The approval indicates that the API has met national technical review standards and can now be sold in the domestic market. This milestone will further diversify the subsidiary's product portfolio, expand the company's business scope, and enhance its integrated API and formulation production capabilities, strengthening its competitive edge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments